Effects of Dapagliflozin, a SGLT2 inhibitor, on Body Composition in Japanese Type 2 Diabetes Patients without severe Obesity

Effects of Dapagliflozin, a SGLT2 inhibitor, on Body Composition in Japanese Type 2 Diabetes Patients without severe Obesity - Effects of Dapagliflozin on Body Composition

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029205

Enrollment

Registered

2017-12-31

Start date

2014-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Dapagliflozin

5mg/day non-SGLT2 inhibitor treatment for DM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 DM HbA1c>7.0% no history of SGLT2 inhibitor-treatment patients with on-going diet and exercise therapies

Exclusion criteria

Exclusion criteria: severe obesity (BMI>35) Type 1 DM ketoacidosis unstable clinical conditions active infection, liver disease, cancer eGFR<45

Design outcomes

Primary

Measure	Time frame
Change in Skeletal Muscle Mass	—

Secondary

Measure	Time frame
Changes in Fat mass, water volume, endothelial function, liver fat content, and kidney function	—

Countries

Japan

Contacts

Public ContactSeigo Sugiyama

Jinnouchi Hospital Diabetes Care Center

seigosugiyama@jinnouchi.or.jp096-363-0011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026